RXRX
Recursion Pharmaceuticals Inc
Mentions (24Hr)
100.00% Today
Reddit Posts
insider trading made 500k filed with SEC should I buy puts?
Nvidia $NVDA has invested $50 million in Recursion Pharmaceuticals $RXRX, an AI drug discovery platform, which has sent its stock up by 78%
RXRX is my pick for the next big thing in AI, what are you betting on?
RXRX short interest only 11%, but a squeeze still playing out…
Insider Trading Weekly Update #028: $DASH CEO, CFO Dump Company Stock, Largest Trades Overall + By Market Sector From The Past Week
RXRX had prior support turned resistance and now we are coming back to that resistance again 29.50 area, just reclaimed 20 SMA will watch for the follow-through move and push over 29.50 and 37.00
RXRX had prior support turned resistance and now we are coming back to that resistance again 29.50 area, just reclaimed 20 SMA will watch for the follow-through move and push over 29.50 and 37.00
Mentions
Fuck ya it is.. congratulations. Last week I made 200$ swinging Intel, SMR and RXRX ( very tiny positions) and never been happier. Losing all my money to bynd stock humbled me and now I'm following a very disciplined pattern.
Hope everyone knows the RXRX train is getting ready to leave the station. recent price predictions: $8-$11 Blackrock and JPMorgan own millions of shares purchased upwards of $5-$7 Current Price: $3.55 Me: A fucking idiot with a phone app
nvida partner with RXRX what happened it tanked
RXRX is worth watching closely here. Short interest remains elevated at roughly 37% of float, days to cover is high (10.6) and institutional ownership is meaningful (56%), which creates the ingredients for a potential squeeze if volume and a real catalyst show up. Not calling it a squeeze yet, but the setup is there and a breakout with confirmation could get interesting fast.
Losses only on short puts and calls alleviated by hedges. I am conflicted on realizing a loss on small RXRX and ANVX positions.
RXRX looks like it’s about to squeeze again but I already sold the kids
Got $4 calls so naturally RXRX will squeeze to $3.9999999
Not sure if my obscure nonsense threat worked but RXRX looks like it’s starting to squeeze
Squeeze RXRX to $5 or the owl gets it
RXRX up 5% since the open...I reiterate this stock is trading below $4 and is primed for a squeeze...
Am I the only one who thinks we should short squeeze Recurssion Pharmaceuticals (RXRX). Stock is trading at $3.65, there’s 174m shares shorted, 37% of the float…and it would take an estimated 9 days for short sellers to cover…it just seems obvious.
Loaded up cheap calls on PATH, RXRX, and BULL
Former CEO has stepped down finally as he was running RXRX into the ground! CMO is also gone! Replaced by 2 ladies that will bring back respectability!
\*NVIDIA INVESTS $2B IN MARVELL TECHNOLOGY Jensen is basically running a tech fund now 🤣 INTC, CRWV, APLD, NBIS, LITE, WRD, RXRX, NOK, OpenAi, Anthropic
Just bought more RXRX Recursion Pharmaceuticals
Recursion Pharmaceuticals (RXRX) $3.12
RXRX SoundHound ARM Got rid of both at break even and one with a bit of gains but had to wait almost 12 months always on negative
LUMN, F, and a biotech, RXRX. I did exit RXRX premiums all but disappeared when the stock fell below $4.00.
Good stuff, buddy. RXRX and ABSI look like candidates for cheap LEAPs with real payoff potential.
AMZN - mainly because of their focus/investment in Robotics GOOG - youtube, AI, is undervalued right now UBER - innovative AUR - almost a leader in autonomous driving (future of trucking) BULL - massive upside, sitting on tons of cash and growing SMCI - i dont really believe in it and I think margin is a problem with them but they have significant upside. Undervalued right now RXRX - innovative, could be big in future ABCL - same reasons Hyundai HYMTF - they own boston dynamics - not easy to invest in this if youre in North America
Hi everyone, I’m a 31-year-old from the Netherlands and recently started investing more actively. I own a house and currently have about €1,500 per month available to invest. I decided to start with a small high-risk / high-reward portfolio while I learn more about the markets. Current positions: • SLS – Sellas Life Sciences• RXRX – Recursion Pharmaceuticals• RBW – Rainbow Rare Earths Total portfolio value: about €1.2k I also have open orders for:• VanEck Gold Miners ETF• VanEck Junior Gold Miners ETF My idea was to combine biotech potential with some exposure to rare earths and gold miners. Goal: long-term learning while taking some calculated risks with small caps. What would you change if this was your starting portfolio?Any diversification ideas or risks I might be overlooking? Thanks!
Everybody go pump RXRX, my March 6 calls are counting on you
Recursion Pharmaceuticals (RXRX) $3.88. RXRX will one day be the Palantir of biotechnology!
Anyone in RXRX? Waiting for earnings call. TBLA too.
Almost like I tried to post DD here about RXRX 1 week ago lmao. Up almost 20% premarket from when I tried to spread the good word.
I posted about RXRX like three days ago with a huge long DD, but got a 3 day ban because “who cares about your small stupid stock.” Mods suck lmao
ALLRIGHTTTTT WHO BOUGHT RXRX? Anyoneeee
Heavy into RXRX tmr morning, Cathie wood usually is the god at predicting shit
RXRX will go up 10 percent after earnings. Here is the reason... Cathy Wood just purchased shares of RXRX and she gives ten percent of her gains to God, who on His part tells her which stocks to buy during prayer time. So its a win-win situation for them both. I'm just tagging along.
Does anyone have the guts or in the slightest of moods to light money on fire and try RXRX for tomorrow?
Anyone have anything to say about RXRX?
Did NVDA sell RXRX too?
Been holding 10k RXRX since like $6 it hit $3 AH after Jensen flushed that turd from Nvidias books. What do I do?
Absolutely RXRX, my target price is minimum 12$
RXRX is such a piece of shit hooooly
#TLDR --- **Ticker:** RXRX **Direction:** Up **Prognosis:** Long Shares / Sell $3 Puts (Targeting $5+) **Catalysts:** REC 4881 results (75% reduction in polyps) & High Short Interest **Risk:** High cash burn (but runway extends to 2027) **OP's Status:** Transfusing blood by day, bagholding bio-pharm by night
"Nvidia picked a stake in RxRx in 2023. " The stake as of their last 13f is $37,607,051. "Nothing has been delivered yet " Their trial results haven't been very good, their pipeline isn't much and at one point they had to curtail a number of things to slow the pace they were going through cash. "Was this just vendor financing" Some of NVDA's investments in recent years have been meaningful, some are not. This is the latter. Long while ago someone asked what people would short and while I didn't short it (should have), my answer was RXRX. It's getting to the point of being too obliterated to bet against and with a 33% short interest any decent news could send it higher but it's not demonstrated a good track record as a public company (and if a similar company was willing to sell to them, what did that say about the future? The stock is about -50% from where that deal happened.)
If you are saying this aloud it means you are probably considering it as an investment. TBH I’ve done pretty good with it. Probably above average returns. But I DCA companies all the time. Right now I flipped it all into RCL, NFLX, and RXRX for a high volatility play. I have hedged my holdings downside so it is capping my return, but a one off release will let it skyrocket when bullishness finally returns.
I don't think you know what high beta means if you're trying to refer to the tech stocks crashing today, SNDK and crew aren't remotely near the top 100 list of highest beta stocks. The only high beta stocks popular with retail are SHOP and RXRX
RECURSION PHARMACEUTICALS (RXRX) will be the big winner!
Swing trading (RXRX, SOUN, GDRX, KOS, considering MARA) and a couple others
RXRX has been bleeding for months and that data platform narrative hasn't saved anyone yet. The squeeze thesis feels forced when the stock can't even hold basic support levels - I'd need to see some actual institutional buying before believing this isn't just another biotech pump attempt.
**This should be SQUEEZED!** **Recursion Pharmaceuticals Inc's (RXRX.NaE)** short interest as a percent of float has risen 7.8% since its last report. According to exchange reported data, there are now **165.73 million shares sold short**, which is 33.73% of all regular shares that are available for trading. Based on its trading volume, **it would take traders 6.14 days to cover their short positions on average**
The short interest is increasing in the stocks RXRX, AI, JACK, MBLY, UAA, LCID, PLAY , etc. what's going on in this increased short interest? Any ideas?
What do you think about RXRX for Monday?
Recursion Pharmaceuticals (RXRX) went up by 7.59% today. I just did some research. There is around 33.56% short interest in this stock i.e., 165.7 million shares approximately as on 31 December 2026. The short sellers should have had a tough time on Thursday. Around 36million shares volume traded on Thursday. This is interesting with that huge short interest.
RXRX stock looks interesting. AI play and pipeline is loaded as well.
i think you are right for the wrong reasons. climate change, natural resource depletion aren't real problems for Investments: climate change isn't that big of a dial for companies (it is for animals habitat and poor nations but not for the sep). natural resource depletion will be a problem in another 100 year maybe the elefant in the room is ai. and in particular AGI/ASI. if we (as of humanity) succesfully build an asi the entire economic sistema of the world will see change drastically. ASI is the most important technology that humans can create, more consequential than fire, agricolture, or electricity. a world whit an asi is a world that dosn't need human work, and where incredible new technology is discovered autonomously at speed unimaginable. the right thing to do is simple by ai stock. my opinion of particular stocks: the best: GOOGLE (50% of my portfolio): has modles, tpu, fsd... very good: TSMC, INTELL, ASML good but not perfect: BROADCOM, NVIDIA, AMAZON, MICROSOFT, TESLA, AMD, MU more risky but potentially interesting: RXRX, OKLO, [z.ai](http://z.ai/), mimimax (and probably a lot more) and i hope for openai, antropi, x1 robbotica, figure and unitree IPOs S&P will probably still be decent but a lot of companies will fail. and more importantly work will be a memory of the past so better have a huge portfolio or live in a country that offers UBI.
so i dont get in further trouble... how about my next money maker RXRX... better!?
IMO, RXRX is a very Cathie Wood stock. It conceptually sounds appealing/exciting theme but when you look at ARKG over the last 5 years, you can see the "hype years" and you can see the years where healthcare is struggling and fundamentals matter. In the latter (2021, 2022, 2024) , the fund has been at the bottom of the category. When you look at the long-term? 3YR/5YR/10YR the fund is at or near the bottom of the category. IMO, if you have one of the greatest growth investing periods that I've ever invested in and the 5 year chart is just a continual erosion, there's something amatter. Recursion merged with peer Exscientia in August 2024. If this was such a compelling area, why would that company sell itself way off the highs? The merger hasn't seemed to help RXRX either. In terms of trials: REC-994 (Cerebral Cavernous Malformation): Recursion's lead candidate failed to demonstrate convincing efficacy in Phase 2. While it met the primary goal of safety, long-term extension data showed no promising trends in MRI or functional outcomes, becoming indistinguishable from natural history. REC-2282 (Neurofibromatosis Type 2): Development was halted after preliminary Phase 2/3 data from the POPLAR-NF2 trial showed limited tumor shrinkage and clinical activity. While the 40mg dose passed a futility threshold, the totality of the data did not justify further investment. REC-3964 (C. difficile Infection): Despite being the first new chemical entity developed through the "RecursionOS" platform, this Phase 2 program was discontinued in May 2025. The company cited a strategic decision to focus on other areas rather than clinical setbacks. REC-4881 (Solid Tumors): A pause was announced for this drug specifically targeting solid tumors, though it remains in development for other indications like FAP (Familial Adenomatous Polyposis) where it has shown more positive results. The company has been around for a bit now and when you look at the pipeline, there is one thing in phase 2, nothing in phase 3, the rest are all phase 1/pre clinical. Looking at a discussion on r/biotech: "Think it came up in another thread, but they just don't give the vibe they know what they're doing in clinical development. It's hard to say it exactly. But somehow they don't talk like they understand how hard it is to actually get something to market and what needs to be done to make that happen." (https://www.reddit.com/r/biotech/comments/1f8icsi/with_few_specifics_recursion_underwhelms_with/ - another thread: https://www.reddit.com/r/biotech/comments/1klmsi1/what_do_you_guys_think_of_recursion/) Also, I wasn't even aware the CEO stepped down a couple mo ago. Again, not saying this is a zero and don't want to be harsh but I just think this is one of those things where the results haven't matched the hype. The stock is 33% short (which says something) so any good news and could get a short squeeze. There is some cash to get through the year and there is a pipeline, but nothing in that pipeline is in stage 3/is seeming to generate that much excitement. IMO, AI around genetic testing (TEM, GH, former ILMN spin off/source of controversy GRAL, NTRA) has been an investment theme that has delivered a lot more than AI drug discovery - at least at this point.
There is Recursion RXRX in the middle and prior to this (Already partnered with Nvidia)
Fair enough! Cathie's biotech plays have been high risk/high reward for a while now. Glad it's working out for you so far—hopefully $RXRX keeps that momentum going.
God I hope my RXRX gets sucked into this for their data set
Who else is patiently waiting for RXRX to make its move in 2026?
I've already mentioned one of them. I bought 2,500@4.22 of RXRX. That's 0.2% of my portfolio, but a fun one that I believe will be lucrative. A couple of other people have followed me on that one, but it's not something you should put a lot of capital into, since it's speculative (but important, because of its AI-driven drug discovery platform, and their apparently successful drug candidate that could get fast tracked by the FDA in H1 2026). I don't think we'll post a portfolio here, since the whole point is to benefit the group that actually does the work, and there will be a lot of it. Good Luck, Durham
RXRX. OPEN is so last year.
Superlatives time. Biggest doodoo stock of the year? My entry: $RXRX YOUR TURN!
RXRX IVVD and NOKIA. ....and SLV lol
Look into IVVD and RXRX, and NOKIA all undervalued.
RXRX; in spite of what Kramer has to say.
RKLB, ASTS, IonQ, Ginkgo Bioworks (DNA), RXRX, ESS Tech (GWH), maybe LUNR, NuScale. Google is my base, IBM too - like the biggest quantum play. I will maybe add TMC.
AI medicine, because they are going to run out of hyped up stocks: RXRX ABCL SDGR ABSI
It doesn't take much to make RKLB or ASTS rocket up 30% for a few weeks before gravity pulls them back. So you can play chicken with boxing those gains before they tech escape velocity and stay up. But what fun is 30% when you can double? POET, RXRX, INVZ.
Haha RXRX gapping up because they made a drug for a disease called FAP
What does RXRX actually do?
bought 15k of RXRX, don't let me down regards!
|Category|Winner|Insight| |:-|:-|:-| |Business Model|**ABCL**|Capital-light, partner-centric| |Data/Tech Moat|**RXRX**|Hardest-to-replicate dataset| |Revenue Visibility|**ABCL**|Milestones + royalties| |Long-term Upside|**RXRX**|If platform works → giant outcome| |Risk Level|**RXRX (high)**|Most speculative| |Financial Strength|**ABCL**|More runway, less burn|
Why not RXRX? RXRX also does AI drug discovery space
Unfortunately I work in this industry and RXRX is a 0. No drug company has demonstrated meaningful ROI from AI. Their compounds in trials are mostly in licensed or repurposed from other companies and programs and are not actually generated from their “AI” platform. Companies like this live and die by trial results and I am far from convinced that any of theirs will succeed.
RXRX is the most moonshotty moonshot I have. AI pharma drug discovery pure play. If it works it'll be explosive.
There are even companies that do it, look at RXRX — they use AI to help with computing potential molecule/receptor binding pairs to find novel compounds with medical significance
!banbet $RXRX $5.80 3w
Lol RXRX is still a thing? I made a quick buck off it a year ago from $6 to mid $9 and then sold it and it tanked again.
Pretty funny if any regards here think they know better than NVIDIA... who basically control the stock market now. No idea what RXRX does but the prolly gonna cure cancer or some shit by January.
I just want out of my RXRX honestly I'm so tired I could've gotten out at 7:15 the other day but I forgot to check it 😩😭
Data infrastructure: VRT Satellites: GSAT and PL No brainer: JPM Covid buy: MPC Next up? Entered ABSI and RXRX today on the heavy heavy dips, entered NRIX back in April. Biotech / drug discovery has been walloped, but these 3 have things going for them. High risk obviously / not investment advice
We gonna know if NVIDIA is the $50m investor for QSI on today. If it is, the weekends is gonna be a blast like RXRX had back in 2023.
That happened in March, almost as soon as I started. I rolled down, often below my basis at the time of selling the call. I was able to collect enough to bring premiums to bring my basis down and still be profitable. I used those premiums to buy other stocks. I did get caught on a couple but not badly. And one of them (RXRX) took a months of grinding, but it's up to positive territory now, basis wise. One was not recoverable - WOLF. But now I know to avoid those. I'm at 40% RoC for RXRX but if I was assigned on Monday, I'd only make 5% net profit on the entire chain that goes back to Feb. I'm at 19% RoC on SOUN and if I was assigned right now, I'd make 45% net profit.
Loaded RXRX heavy. It’s long hold.
Can’t wait for RXRX earnings Wed morning! Holding 8k shares….
RXRX earnings on Wednesday.
RLAY and RXRX pharma and AI. Also AI.